By Dean Seal
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy.
The stock was up 9.5% at 1.28 in premarket trading. Shares had fallen 25% year-to-date when the market closed last week.
The clinical-stage biopharma company said Monday that the Food and Drug Administration has lifted a clinical hold on ENTR-601-44 and authorized a Phase 1b clinical study of it as a potential treatment for Duchenne muscular dystrophy in certain adult patients.
"Given the strength of our safety and target engagement data from our Phase 1 clinical study and the profound unmet need in adults living with Duchenne, we are pleased to have obtained FDA clearance," Chief Executive Dipal Doshi said.
Entrada plans to launch enrollment for the study in the first half of 2026.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 24, 2025 07:32 ET (12:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。